1. Market Research
  2. > Biotechnology Market Trends
  3. > China Human Vaccine Industry Report, 2016-2020

China Human Vaccine Industry Report, 2016-2020

  • June 2016
  • -
  • Research In China
  • -
  • 151 pages

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in domestic vaccine supply capacity and vaccine circulation safety, China’s human vaccine import volume has showed a year-by-year decline in recent years, with the imports for 2015 totaling 173.9 tons, down 17.5% year on year.

Affected by China’s less-developed economy, existing national vaccine prevention policies and people’s awareness of epidemic prevention, free EPI vaccines prevail in China. But the market share is falling, with the free EPI vaccine lot release volume in 2015 accounting for about 74.3% of the total. The Chinese free human vaccine market is still dominated by the subsidiaries of China National Biotec Group—including Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., and Changchun Institute of Biological Products Co., Ltd.—and state-owned enterprises like Institute of Medical Biology under Chinese Academy of Medical Sciences. In 2015, the EPI vaccine lot release volume of Chinese state-owned enterprises made up 72.6% of the total.

However, as China gradually relaxes controls on the vaccine market, private companies have unexpectedly emerged in extra EPI vaccine market segment in recent years, with the proportion increasing constantly. In 2015, their lot release volume accounted for 70% in this market segment. Furthermore, these enterprises hold a dominant position in haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, influenza vaccine, and other market segments.

Being upbeat about China’s human vaccine demand market and exports, many vaccine producers are stepping up vaccine R&D or expanding capacity.

So far, there are four enterprises in China, namely Walvax Biotechnology, Beijing Minhai Biotechnology, SINOVAC BIOTECH, and Lanzhou Institute of Biological Products, whose 13-valent pneumococcal conjugate vaccine (PCV13) have entered clinical research stage; recombinant HPV vaccines, developed by Shanghai Zerun Biotechnology, a subsidiary of Walvax Biotechnology, and Xiamen Innovax Biotech, have entered phase III clinical research phase.

In 2015, CFDA approved the production and registration application of the world's first inactivated Sabin strain polio vaccine, which was developed by the Institute of Medical Biology of the Academy of Medical Sciences. The vaccine was brought to market on June 30, 2015. Over the same year, the inactivated enterovirus 71 (EV71) vaccines (for hand-foot-mouth disease prevention), also developed by the Institute of Medical Biology of the Academy of Medical Sciences was made available after the approval from CFDA; SINOVAC BIOTECH and Wuhan Institute of Biological Products are applying for drug production license of inactivated enterovirus 71 (EV71) vaccines; Hualan Bio and Beijing ZhifeiLvzhu Biopharmaceutical (a subsidiary of Chongqing Zhifei Biological Products) have submitted the application of clinic trial of inactivated enterovirus 71 (EV71) vaccines.

China Human Vaccine Industry Report, 2016-2020 highlights the following:

Operating environment, overall situation, sales channel, etc. of China human vaccine industry;
Supply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
Supply & demand, competitive landscape, and market prices of 10 vaccine product segments in China, including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine;
Operation, vaccine business, and development prospects of 16 Chinese human vaccine companies.

Table Of Contents

China Human Vaccine Industry Report, 2016-2020
1. Overview of Vaccine Industry
1.1 Definition and Classification
1.2 Industry Chain

2. China Human Vaccine Industry and Market
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.2.3 Biopharmaceutical Market in China
2.3 Status Quo
2.4 Supply and Demand
2.5 Competition Pattern
2.6 Dynamics
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply and Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccines
3.2.1 Supply and Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply and Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply and Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply and Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Rabies Vaccine
3.6.1 Supply and Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply and Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccines
3.8.1 Supply and Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DTP Vaccine
3.9.1 Supply and Demand
3.9.2 Competition Pattern
3.9.3 Market Dynamics and Forecast
3.10 PoliomyelitisVaccine
3.10.1 Supply and Demand
3.10.2 Competition Pattern

4. China's Import and Export of Vaccines
4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Country and Region
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Import Country and Region

5. Major Vaccine Manufacturers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd
5.1.2 Chengdu Institute of Biological Products Co., Ltd.
5.1.3 Shanghai Institute of Biological Products Co., Ltd.
5.1.4 Wuhan Institute of Biological Products Co., Ltd.
5.1.5 Lanzhou Institute of Biological Products Co., Ltd.
5.1.6 Changchun Institute of Biological Products Co., Ltd.
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Clients and Suppliers
5.2.6 RandD Cost and Investment
5.2.7 Vaccine Business
5.2.8 Development and Prospects
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Clients
5.3.6 RandD Cost and Investment
5.3.7 Development and Prospects
5.4 Walvax Biotechnology Co, Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Clients and Suppliers
5.4.6 RandD Cost and Investment
5.4.7 Development and Prospects
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 RandD Cost and Investment
5.5.5 Development and Prospects
5.6 Liaoning Cheng Da Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Clients
5.6.6 Liaoning Chengda Biotechnology Co., Ltd.
5.6.7 Development and Prospects
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-Pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation
5.12 NCPC GeneTech Biotechnology Development Co., Ltd.
5.12.1 Profile
5.12.2 Operation
5.13 Dalian Aleph Biomedical Co., Ltd.
5.13.1 Profile
5.13.2 Operation
5.14 Beijing Minhai Biotechnology Co., Ltd.
5.14.1 Profile
5.14.2 Operation
5.15 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
5.15.1 Profile
5.15.2 Operation
5.16 Jiangsu SimcereVaxtec Bio-pharmaceutical Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Western Blotting Market by Product, Application, End User - Global Forecasts to 2021

Western Blotting Market by Product, Application, End User - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The western blotting market is projected to reach USD 730.7 million by 2021 from USD 574.8 million in 2016, at a CAGR of 4.9% in the next five years (2016 to 2021). The western blotting market is undergoing ...

Transfection Reagents and Equipment Market by Method, Physical, Viral, Application, End User - Global Forecast to 2021

Transfection Reagents and Equipment Market by Method, Physical, Viral, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global transfection reagents and equipment market is expected to reach USD 1.02 billion by 2021 from USD 715.4 million in 2016, at a CAGR of 7.5% during the forecast period 2016 to 2021. Over the years, ...

Global In-Vitro Toxicology Testing Market

Global In-Vitro Toxicology Testing Market

  • $ 4250
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The Global Intra Uterine contraceptive Devices market is estimated to be USD 1,370 million in 2016 and is expected to reach USD 2,267 million by 2021, growing at a compound annual growth rate (CAGR) of ...

Global Genetic Testing Market

December 2016 $ 4250

Enzymes Markets In China

February 2017 $ 4000

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.